Pelabresib
Pelabresib is a pharmaceutical drug with 8 clinical trials. Currently 4 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
0
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
2 of 2 finished
0.0%
0 ended early
4
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
Clinical Trials (8)
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
All 8 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 8